Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

C. Marcela Díaz‐Montero, Mohamed L. Salem, Michael I. Nishimura et al. · Cancer Immunology Immunotherapy · 2008 · 1.2K citations

Medicine, Cancer Biology, Oncology +17

Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang et al. · Clinical Cancer Research · 2014 · 782 citations

Medicine, Genetics, Oncology +17

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Jean‐Yves Douillard, Gyula Ostoros, Manuel Cobo et al. · Journal of Thoracic Oncology · 2014 · 445 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study

Christine Parkinson, Davina Gale, Anna Piskorz et al. · PLoS Medicine · 2016 · 300 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Association of<i>EGFR</i>L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Niki Karachaliou, Clara Mayo-de las Casas, Cristina Queralt et al. · JAMA Oncology · 2015 · 238 citations · Full text

Medicine, Molecular Biology, Oncology +17